HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA

• Main Authors: SALFELD, JOCHEN G, ALLEN, DEBORAH J, ROBERTS, ANDREW J, MCGUINNESS, BRIAN T, VAUGHAN, TRISTAN J, HOOGENBOOM, HENDRICUS R.J.M, MANKOVICH, JOHN A, LABKOVSKY, BORIS, SCHOENHAUT, DAVID, KAYMAKCALAN, ZEHRA, WHITE, MICHAEL, SAKORAFAS, PAUL, WILTON, ALISON J
• Format: Patent
• Language: English; French; German
• Published: 14.10.2015
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ± (hTNF±) are disclosed. These antibodies have high affinity for hTNF± (e.g., K d = 10 -8 M or less), a slow off rate for hTNF± dissociation (e.g., K off = 10 -3 sec -1 or less) and neutralize hTNF± activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNF± and for inhibiting hTNF± activity, e.g., in a human subject suffering from a disorder in which hTNF± activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.